Literature DB >> 12021120

Low frequency of autoantibodies to islet cell, glutamic acid decarboxylase, and second-islet antigen in patients with gestational diabetes mellitus: a follow-up study.

A Lapolla1, D Fedele, B Pedini, M G Dal Fra, M Sanzari, M Masin, R Zanchetta, C Betterle.   

Abstract

The aim of the study was to determine the frequency of patients with gestational diabetes mellitus (GDM) who have serological markers typical of autoimmune type 1 DM. The specific pancreatic markers, ICAs, glutamic decarboxylase (GADAbs), and second islet antigen (IA2Abs), were measured in 70 women with GDM during the pregnancy and after delivery. ICAs were measured by indirect immunofluorescence and GADAbs and IA2Abs were determined by a radiobinding assay with recombinant antigens. On entering the study, 1 of 70 (1.4%) patients was positive for both ICAs (80 JDF-U) and GADAbs (167 U/mL), while another (1.4%) was positive for ICAs (40 JDF-U). None of the patients was positive for IA2Abs. During follow-up, positivity was maintained unchanged in the two positive patients. Four previously negative patients had seroconversion: one for both ICAs (20 JDF-U) and GADAbs (49.3 U/mL) and the other three for GADAbs (1.8, 1.4, and 15.3 U/mL, respectively). The IA2Abs remained negative in all patients. Overall, during the observation period 6 of 70 (8.6%) patients had or developed autoantibodies against endocrine pancreas. During follow-up 15 patients developed clinical DM (10 type 2, 5 type 1) and 7 demonstrated impaired glucose tolerance (IGT) after OGTT. No correlations were demonstrated between the immunological patterns and the evolution in DM. In patients with GDM, the frequency of pancreatic autoantibodies varies during the pregnancy and after delivery, but a small subgroup of patients bearing these markers is identifiable. GDM is a complex syndrome, constituted by different types of diabetes mellitus where the autoimmune form is very rare.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12021120     DOI: 10.1111/j.1749-6632.2002.tb02983.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  6 in total

Review 1.  Clinical Recommendations for the Use of Islet Cell Autoantibodies to Distinguish Autoimmune and Non-Autoimmune Gestational Diabetes.

Authors:  Kadri Haller-Kikkatalo; Raivo Uibo
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

2.  Presence of diabetes-specific autoimmunity in women with gestational diabetes mellitus (GDM) predicts impaired glucose regulation at follow-up.

Authors:  E Cossu; M Incani; M G Pani; G Gattu; C Serafini; A Strazzera; L Bertoccini; F A Cimini; I Barchetta; M G Cavallo; M G Baroni
Journal:  J Endocrinol Invest       Date:  2018-01-16       Impact factor: 4.256

3.  Gestational diabetes and thyroid autoimmunity.

Authors:  Ester Vitacolonna; Annunziata Lapolla; Barbara Di Nenno; Annalisa Passante; Ines Bucci; Cesidio Giuliani; Dominique Cerrone; Fabio Capani; Fabrizio Monaco; Giorgio Napolitano
Journal:  Int J Endocrinol       Date:  2012-05-13       Impact factor: 3.257

4.  Autoimmunity in gestational diabetes mellitus in Sardinia: a preliminary case-control report.

Authors:  Cinzia Murgia; Marisa Orrù; Elaine Portoghese; Nicoletta Garau; Pierina Zedda; Rachele Berria; Costantino Motzo; Simonetta Sulis; Michela Murenu; Anna Maria Paoletti; Gian Benedetto Melis
Journal:  Reprod Biol Endocrinol       Date:  2008-06-29       Impact factor: 5.211

5.  Testing for type 1 diabetes autoantibodies in gestational diabetes mellitus (GDM): is it clinically useful?

Authors:  Michela Incani; Marco Giorgio Baroni; Efisio Cossu
Journal:  BMC Endocr Disord       Date:  2019-05-03       Impact factor: 2.763

6.  Celiac Disease and Pregnancy Outcomes in Patients with Gestational Diabetes Mellitus.

Authors:  Maria Grazia Dalfrà; Gloria Giovanna Del Vescovo; Silvia Burlina; Ilaria Baldan; Silvia Pastrolin; Annunziata Lapolla
Journal:  Int J Endocrinol       Date:  2020-10-16       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.